AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the successful closing of an oversubscribed $60 million financing round, which brings the total Series A funding to $90 million. The financing was led by Forbion with participation from Ono Venture Investment, Alexandria Venture Investments, and other new investors, as well as AIRNA’s existing syndicate, including ARCH Venture Partners and ND Capital. The proceeds from the Series A financing will be used to advance AIRNA’s lead product candidate into clinical trials and further develop AIRNA’s broad pipeline.